Skip to main content
OpenTrials
Completed

NCT Number: NCT02229474

IDEA Study Cognitive Stimulation Therapy (CST) Trial in Tanzania

This trials of cognitive stimulation therapy (CST) in Tanzania is part of the larger Identification and Intervention for Dementia in Elderly Africans (IDEA) study.

The overall aim of the IDEA study is to set up and evaluate sustainable programmes to facilitate diagnosis of, and therapy for, people with dementia led by local communities in sub-Saharan Africa. We aim seek to improve quality of life for people with dementia and their caregivers.

Within this trial of CST, we hypothesise that CST can significantly improve the quality of people with dementia and their carers living in Africa

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hai district DSS

Moshi, Kilimanjaro, Tanzania

About this study

Our project will address three specific challenges: 1) Integrate screening and core packages of services into routine primary health care. 2) Provide effective and affordable community-based care and rehabilitation. 3) Develop effective treatment for use by non-specialists, including lay healthcare workers with minimal training.

Dementia is under-diagnosed in sub-Saharan Africa (SSA) and treatment is rarely accessed or available. The burden of dementia on caregivers is high, with loss of income, and psychosocial stress common. However, large scale screening for dementia in such a setting is neither affordable nor sustainable. The purpose of this 3 year project is to provide a sustainable mechanism for diagnosis and therapeutic intervention for people with dementia. We will use 2 complimentary, rural study sites, 1 in Nigeria, West Africa and 2 in Tanzania, East Africa. As a consequence our results should be generalizable to all SSA. Our approach is inexpensive and will have applicability to other low- and middle-income countries.

During Phase I we will validate a screening tool, previously developed by members of our study team from data collected in Tanzania, and carry out a pilot study of the benefits of cognitive stimulation therapy (CST) when used in SSA for those already identified with dementia. During both of these activities we will initiate training of local healthcare workers in diagnosis and management of people with dementia. In Phase II we will engage with local communities to raise awareness of dementia. Building on previous work at both study sites, we will initiate poster, newspaper and radio advertising and use mobile phone text messaging services (for relevant healthcare personnel) to increase awareness of the need to diagnose and intervene at an early stage. We will empower local private pharmacies to help identify people with dementia, a relationship which will ultimately be mutually beneficial through the supply of medicines to treat risk factors for dementia, such as hypertension. We will engage with local community leaders and government officials to assist us in this awareness raising, an approach that has proven successful in previous studies by our team in SSA. One of our study team (Dr Mushi (DM)) is a social scientist based in Tanzania and during Phase II we will conduct qualitative research into attitudes and beliefs surrounding dementia and identify any barriers to diagnosis in both sites. The results of this research will be fed back to inform other phases of the study. Finally, in phase III we will initiate a program of community based CST led by local occupational therapists (OTs) and nurse specialists. OTs and nurses will train caregivers in CST techniques and we hope that the training will ultimately be led by caregivers allowing such therapy to become sustainable within communities in the longer term. We will evaluate changes in cognition in people with dementia, and quality of life (QOL) in both people with dementia and their caregivers, post-intervention. We will carry out a full economic evaluation of the effect of our program, to be led by a heath economist based at Newcastle University, United Kingdom.

This protocol cover the CST trial (Phase III of the study) in Tanzania

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Anyone with dementia living within the study site

Exclusion criteria

  • The participant and the family should have consented to take part in the study.
  • Unable to travel to the centre where the CST sessions will be held due to physical impairment (e.g. bedbound or immobile)
  • After assessment by the study doctor, deemed unable to engage in CST sessions (e.g. follow instructions and participate in activities) due to severe physical or cognitive impairment.
  • Profound deafness
  • Total blindness
  • Aphasia - they should be able to understand verbal communication and communicate verbally (mild impairments are acceptable).
  • The participant should be able to sit in a group setting for 1 hour.
  • There should not be agitation, depression or psychosis to an extent that the person would not be able to tolerate spending time with other people in a group setting.

Treatment and study plan

CST Intervention

Behavioral

The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.

Primary outcomes

  1. World Health Organization Brief Quality of Life Scale

    Time frame: Baseline

    The WHOQOL-Bref will assess quality of life in patients and carers. The scale is scored from a minimum of 4 to a maximum of 20, with higher scores indicating better quality of life. The scores are measured as units on a scale

  2. World Health Organization Brief Quality of Life Scale

    Time frame: Immediately post-intervention

    The WHOQOL-Bref will assess quality of life in patients and carers. The WHOQOL-Bref will assess quality of life in patients and carers. The scale is scored from a minimum of 4 to a maximum of 20, with higher scores indicating better quality of life. The scores are measured as units on a scale

Secondary outcomes

  1. World Health Organization Brief Quality of Life Scale

    Time frame: Four weeks post intervention

    The scale will assess quality of life in patients and carers. The scale is scored from a minimum of 4 to a maximum of 20, with higher scores indicating better quality of life. The scores are measured as units on a scale.

  2. Identification and Intervention for Elderly Africans Cognitive Screen

    Time frame: Baseline

    The screen will assess cognitive function. It is scored from a minimum of 0 to a maximum of 15, with a higher score indicating better cognitive function.

  3. Adapted Alzheimer's Disease Assessment Scale-cognitive Scale

    Time frame: Baseline

    The adapted scale will assess cognitive function, specifically change in function over time. The minimum possible score is 0 and the maximum is 69. A lower score indicates better cognitive function.

  4. Hospital Anxiety and Depression Scale

    Time frame: Baseline

    The scale will assess anxiety and depression in patients and carers. The maximum possible score is 21 and the minimum score is 0. Lower score indicates lower levels of anxiety and depression.

  5. Zarit Burden Interview

    Time frame: Baseline

    The scale will assess carer burden. There are 22 questions each scored from 0 to 4. Overall, the scale is scored from 0 to 88, with a higher score indicating greater burden.

  6. Identification and Intervention for Elderly Africans Cognitive Screen

    Time frame: Immediately post-intervention

    The screen will assess cognitive function. It is scored from a minimum of 0 to a maximum of 15, with a higher score indicating better cognitive function.

  7. Adapted Alzheimer's Disease Assessment Scale-cognitive Scale

    Time frame: Immediately post-intervention

    The adapted scale will assess cognitive function, specifically change in function over time. The minimum possible score is 0 and the maximum is 69. A lower score indicates better cognitive function.

  8. Hospital Anxiety and Depression Scale

    Time frame: Immediately post-intervention

    The scale will assess anxiety and depression in patients and carers. The maximum possible score is 21 and the minimum score is 0. Lower score indicates lower levels of anxiety and depression.

  9. Zarit Burden Interview

    Time frame: Immediately post-intervention

    The scale will assess carer burden. There are 22 questions each scored from 0 to 4. Overall, the scale is scored from 0 to 88, with a higher score indicating greater burden.

Sponsors and collaborators

Lead sponsor

William Keith Gray

Other

Collaborators

  • Grand Challenges Canada
  • Kilimanjaro Christian Medical Centre, Tanzania
  • Newcastle University
  • Northumbria Healthcare NHS Foundation Trust
  • University of Ibadan

Registry information

Official study title

Identification and Intervention for Dementia in Elderly Africans (IDEA) Study: CST Trial

Acronym: IDEA

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Sep 1, 2014
Registry last updated
Apr 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.